Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.

Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, McNamee K, Garefalakis M, Phillips S, Cummins E, Malloy M, Garland SM.

Lancet Infect Dis. 2014 Oct;14(10):958-66. doi: 10.1016/S1473-3099(14)70841-2. Epub 2014 Aug 5.

PMID:
25107680
2.

Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.

Chow EP, Danielewski JA, Fehler G, Tabrizi SN, Law MG, Bradshaw CS, Garland SM, Chen MY, Fairley CK.

Lancet Infect Dis. 2015 Nov;15(11):1314-23. doi: 10.1016/S1473-3099(15)00055-9. Epub 2015 Jul 19.

PMID:
26201300
3.

Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.

Chow EPF, Machalek DA, Tabrizi SN, Danielewski JA, Fehler G, Bradshaw CS, Garland SM, Chen MY, Fairley CK.

Lancet Infect Dis. 2017 Jan;17(1):68-77. doi: 10.1016/S1473-3099(16)30116-5. Epub 2016 Jun 6.

PMID:
27282422
4.

Fall in human papillomavirus prevalence following a national vaccination program.

Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM.

J Infect Dis. 2012 Dec 1;206(11):1645-51. doi: 10.1093/infdis/jis590. Epub 2012 Oct 19.

PMID:
23087430
5.

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.

Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, Bhatia R, Moore C, Cubie H, Cruickshank M, Robertson C.

Lancet Infect Dis. 2017 Dec;17(12):1293-1302. doi: 10.1016/S1473-3099(17)30468-1. Epub 2017 Sep 28.

PMID:
28965955
6.

Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.

Osborne SL, Tabrizi SN, Brotherton JM, Cornall AM, Wark JD, Wrede CD, Jayasinghe Y, Gertig DM, Pitts MK, Garland SM; VACCINE Study group.

Vaccine. 2015 Jan 1;33(1):201-8. doi: 10.1016/j.vaccine.2014.10.045. Epub 2014 Nov 1.

PMID:
25444787
7.

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.

Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, Ahmed S, Palmer T, Pollock KG.

Emerg Infect Dis. 2016 Jan;22(1):56-64. doi: 10.3201/eid2201.150736.

8.

HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.

Tabrizi SN, Brotherton JM, Stevens MP, Condon JR, McIntyre P, Smith D, Garland SM; WHINURS group.

J Clin Virol. 2014 Jul;60(3):250-6. doi: 10.1016/j.jcv.2014.04.013. Epub 2014 May 5.

PMID:
24854516
9.

Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.

Kahn JA, Widdice LE, Ding L, Huang B, Brown DR, Franco EL, Bernstein DI.

Clin Infect Dis. 2016 Nov 15;63(10):1281-1287. Epub 2016 Sep 20.

10.

Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.

Gunasekaran B, Jayasinghe Y, Brotherton JM, Fenner Y, Moore EE, Wark JD, Fletcher A, Tabrizi SN, Garland SM.

Vaccine. 2015 Feb 4;33(6):826-31. doi: 10.1016/j.vaccine.2014.11.002. Epub 2014 Nov 12.

PMID:
25444782
11.

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.

BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-227.

12.

Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection.

Korostil IA, Peters GW, Law MG, Regan DG.

Vaccine. 2013 Apr 8;31(15):1931-6. doi: 10.1016/j.vaccine.2013.02.018. Epub 2013 Feb 19.

PMID:
23434388
13.

Prevalence of Human Papillomavirus in Self-Collected Cervicovaginal Swabs in Young Women in the United States Between 2003 and 2012.

Tarney CM, Klaric J, Beltran T, Pagan M, Han J.

Obstet Gynecol. 2016 Dec;128(6):1241-1247.

PMID:
27824760
14.

Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.

Oliver SE, Unger ER, Lewis R, McDaniel D, Gargano JW, Steinau M, Markowitz LE.

J Infect Dis. 2017 Sep 1;216(5):594-603. doi: 10.1093/infdis/jix244.

PMID:
28931217
15.

No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.

Woestenberg PJ, King AJ, van der Sande MA, Donken R, Leussink S, van der Klis FR, Hoebe CJ, Bogaards JA, van Benthem BH; Medical Microbiological Laboratories; Public Health Services.

J Infect. 2017 Apr;74(4):393-400. doi: 10.1016/j.jinf.2017.01.007. Epub 2017 Jan 23.

16.

Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.

Carozzi F, De Marco L, Gillio-Tos A, Del Mistro A, Girlando S, Baboci L, Trevisan M, Burroni E, Grasso S, Giorgi Rossi P, Ronco G; NTCC Working Group.

J Clin Virol. 2014 Jul;60(3):257-63. doi: 10.1016/j.jcv.2014.04.009. Epub 2014 Apr 18.

PMID:
24815381
17.

Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.

Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, Bernstein DI.

Pediatrics. 2012 Aug;130(2):e249-56. doi: 10.1542/peds.2011-3587. Epub 2012 Jul 9.

18.

Change in Human Papillomavirus Prevalence Among U.S. Women Aged 18-59 Years, 2009-2014.

Berenson AB, Hirth JM, Chang M.

Obstet Gynecol. 2017 Oct;130(4):693-701. doi: 10.1097/AOG.0000000000002193.

PMID:
28885413
19.

Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.

Heard I, Tondeur L, Arowas L, Demazoin M, Falguières M, Parent Du Chatelet I; pour le groupe CHlaHPV.

J Infect Dis. 2017 Mar 1;215(5):757-763. doi: 10.1093/infdis/jiw639.

PMID:
28011911
20.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

Supplemental Content

Support Center